Association of Schistosoma haematobium and Human Papillomavirus in Cervical Cancer

Savardekar, Lalita; Donta, Balaiah; Mali, B N

doi:10.1159/000325011

Cited by 14 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also important to recognise that urogenital schistosomiasis may have a role in human immunodeficiency virus (HIV) and human papillomavirus (HPV) infections [81–83] and could potentially make co-infected individuals more infectious [82, 84]. This suggests that community-wide treatment for schistosomiasis could have benefits on other diseases - which are not captured in this study.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the variation in the projected benefit of community-wide mass treatment for schistosomiasis: Implications for future economic evaluations

et al. 2017

View full text Add to dashboard Cite

BackgroundThe majority of schistosomiasis control programmes focus on targeting school-aged children. Expanding the use of community-wide mass treatment to reach more adults is under consideration. However, it should be noted that this would require a further increase in programmatic resources, international aid, and commitment for the provision of praziquantel. Consequently, it is important to understand (i) where a change of strategy would have the greatest benefit, and (ii) how generalisable the conclusions of field trials and analytical studies based on mathematical models investigating the impact of community-wide mass treatment, are to a broad range of settings.MethodsIn this paper, we employ a previously described deterministic fully age-structured schistosomiasis transmission model and evaluate the benefit of community-wide mass treatment both in terms of controlling morbidity and eliminating transmission for Schistosoma mansoni, across a wide range of epidemiological settings and programmatic scenarios. This included variation in the baseline relative worm pre-control burden in adults, the overall level of transmission in defined settings, choice of effectiveness metric (basing morbidity calculations on prevalence or intensity), the level of school enrolment and treatment compliance.ResultsCommunity-wide mass treatment was found to be more effective for controlling the transmission of schistosome parasites than using a school-based programme only targeting school-aged children. However, in the context of morbidity control, the potential benefit of switching to community-wide mass treatment was highly variable across the different scenarios analysed. In contrast, for areas where the goal is to eliminate transmission, the projected benefit of community-wide mass treatment was more consistent.ConclusionWhether community-wide mass treatment is appropriate will depend on the local epidemiological setting (i.e. the relative pre-control burden in adults and transmission intensity), and whether the goal is morbidity control or eliminating transmission. This has important implications regarding the generalisability of cost-effectiveness analyses of schistosomiasis interventions. Our results indicate that areas with poor school-enrolment/coverage could benefit more from community-wide treatment of praziquantel and should potentially be prioritised for any change in strategy. This work highlights the importance of not over-generalising conclusions and policy in this area, but of basing decisions on high quality epidemiological data and quantitative analyses of the impact of interventions in a range of settings.Electronic supplementary materialThe online version of this article (doi:10.1186/s13071-017-2141-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating the variation in the projected benefit of community-wide mass treatment for schistosomiasis: Implications for future economic evaluations

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Additionally, the role of urogenital schistosomiasis in human immunodeficiency virus (HIV) and possibly, human pampillomavirus (HPV) infection has recently been recognized. [9][10][11][12] Disruption of the genital tract epithelium caused by S. haematobium eggs has been associated with increased risk for acquiring HIV infection. Some studies have suggested that the SH infection can result in increased viral loads of HIV or HPV, which could result in the increased ability of the infected persons to transmit these viruses to others.…”

Section: Discussionmentioning

confidence: 99%

Assessing the WHO 50% Prevalence Threshold in School-Aged Children as Indication for Treatment of Urogenital Schistosomiasis in Adults in Central Nigeria

Evans

King²,

Eigege³

et al. 2013

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Preventive chemotherapy with praziquantel is recommended in adults by the World Health Organization when prevalence of schistosomiasis in school-aged children (SAC) is 50%. This study ascertained the value of this threshold in predicting prevalence and intensity of Schistosoma hematobium (SH) infection in adults in central Nigeria. We evaluated urogenital schistosomiasis prevalence in 1,164 adults: 659 adults in 12 communities where mean hematuria among SAC in 2008 was 26.6% and 505 adults in 7 communities where the mean hematuria among SAC in 2008 was 70.4%. No statistically significant differences were found between the two groups of adults in prevalence of hematuria, prevalence of SH eggs, or intensity of infections. We conclude that, in this setting, the SAC threshold is not useful for treatment decisions in adults. Given the increased risk of subtle morbidity or urogenital schistosomiasis as a risk factor for human immunodeficiency virus (HIV), more liberal treatment of adults with praziquantel is warranted.

show abstract

“…5,9 However, there is no convincing evidence that schistosomiasis can independently have a carcinogenetic effect without HPV. 8,10,11 Not all clinical symptoms suggestive of tumour recurrence in a patient with cancer can be assumed. Other medical conditions, such as infection, can be present, and the clinician must be aware that these can mimic tumour recurrence.…”

Section: 4mentioning

confidence: 99%

Schistosoma haematobium in a human immunodeficiency virus-positive patient with cancer of the cervix

Hocepied

Lakier

2013

Southern African Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Association of Schistosoma haematobium and Human Papillomavirus in Cervical Cancer

Cited by 14 publications

References 19 publications

Evaluating the variation in the projected benefit of community-wide mass treatment for schistosomiasis: Implications for future economic evaluations

Evaluating the variation in the projected benefit of community-wide mass treatment for schistosomiasis: Implications for future economic evaluations

Assessing the WHO 50% Prevalence Threshold in School-Aged Children as Indication for Treatment of Urogenital Schistosomiasis in Adults in Central Nigeria

Schistosoma haematobium in a human immunodeficiency virus-positive patient with cancer of the cervix

Contact Info

Product

Resources

About